Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Form 8-K on March 26, 2020, reporting the effective implementation of a reverse stock split. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Reverse Stock Split: A 1-for-14 reverse stock split of outstanding common stock became effective at 5:01 p.m. Eastern Time on March 26, 2020.
- Share Consolidation: Every 14 shares of issued and outstanding common stock were automatically combined into one share without a change in par value.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on March 27, 2020, under the new CUSIP number 03835L207.
- Equity Instruments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options, restricted stock units, and warrants. The number of shares reserved under equity compensation plans was reduced proportionately.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the reverse stock split, which are subject to risks and uncertainties. The company notes that actual results may differ materially from expectations due to factors such as delays in regulatory approvals. The company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the new CUSIP number (03835L207) for post-split trading.
- Confirm the adjusted exercise prices and share counts for any held options, warrants, or RSUs.
- Check for cash payments received in lieu of fractional shares if applicable.
- Review the attached Certificate of Amendment (Exhibit 3.1) for the full legal text of the corporate action.